Sucrose-Formulated Recombinant Factor VIII Dosing Flexibility in Prophylaxis Regimens: Experience from Postmarketing Surveillance Studies

Table 3

Annualized bleeding rates by dosing and age subgroups.

Annualized bleeding rates	Prophylaxis		Prophylaxis
	1-2x/wk		≥3x/wk
	()		()
	Age <18 y	Age ≥18 y	Age <18 y	Age ≥18 y
All bleeds
Mean ± SD	3.0 ± 5.6	5.0 ± 6.9	5.8 ± 5.9	8.7 ± 14.7
Median (Q1; Q3)	1.9 (0; 3.0)	2.4 (0; 8.4)	3.5 (1.1; 8.5)	4.7 (1.9; 11.2)
Joint bleeds
Mean ± SD	1.5 ± 3.4	3.9 ± 6.1	2.9 ± 3.2	6.6 ± 9.6
Median (Q1; Q3)	0.5 (0; 1.5)	1.7 (0; 3.5)	1.8 (0.5; 4.2)	3.8 (1.5; 8.5)
Spontaneous bleeds
Mean ± SD	0.5 ± 1.0	3.9 ± 6.3	1.1 ± 2.2	5.8 ± 8.5
Median (Q1; Q3)	0 (0; 0.5)	1.1 (0; 6.8)	0.5 (0; 1.0)	3.0 (0; 8.8)
Trauma-related bleeds
Mean ± SD	2.4 ± 5.1	1.1 ± 1.9	4.3 ± 4.5	2.4 ± 6.2
Median (Q1; Q3)	1.0 (0; 2.4)	0 (0; 1.1)	2.5 (0.9; 7.0)	0.7 (0; 1.9)

Q1 = quartile 1; Q3 = quartile 3.